Cognition Therapeutics Inc (CGTX): Cash & Equivalents
$36.81M
As of 2025-12-31
$34.01M
As of 2026-06-30
-4.0%
3-year compound annual growth
+48.0%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $36.81M | +47.2% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $25.01M | -16.4% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $29.92M | -28.0% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $41.56M | -24.0% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $54.72M | +954.6% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $5.19M | n/a | 2022-03-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Cognition Therapeutics Inc (CGTX) | 2025-12-31 | $36.81M | +47.2% |
| PharmaCyte Biotech, Inc. (PMCB) | 2026-04-30 | $18.60M | +22.6% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $16.42M | -66.0% |
| Viskase Holdings, Inc. (VISK) | 2025-12-31 | $42.57M | -9.1% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $20.95M | -50.0% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $17.47M | -66.1% |
| Passage BIO, Inc. (PASG) | 2025-12-31 | $46.30M | +23.2% |
| Elutia Inc. (ELUT) | 2025-12-31 | $36.35M | +174.6% |
| Jasper Therapeutics, Inc. (JSPR) | 2025-12-31 | $28.69M | -59.9% |
Compare CGTX, PMCB, SNTI, VISK side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗